Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Thu, July 30, 2026 at 4:38 PM GMT+3 4 min read

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Leerink upgraded Humana (HUM) to Outperform from Market Perform with a $513 price target. Looking at probable earnings power scenarios for 2028, the firm contends that the valuation compared to its current 2028 estimate of about $31 in EPS is "too attractive." Piper Sandler also upgraded Humana to Overweight from Neutral with a price target of $463, up from $254.

• Mizuho upgraded Bloom Energy (BE) to Outperform from Neutral with a price target of $242, down from $285. The company reported a strong quarter, with revenue and shipments beating expectations, the firm tells investors in a research note.

• JPMorgan upgraded Sprouts Farmers Market (SFM) to Overweight from Neutral with a price target of $103, up from $80, following the Q2 report. The company's sales growth is at a "positive inflection point," which could help drive a re-rating in the shares, the firm tells investors in a research note.

• Wolfe Research upgraded uniQure (QURE) to Outperform from Peer Perform with a $65 price target. The stock has priced in less than 50% odds of success for approval amid concerns stemming from the recent advisory committees, but uniQure has "a stronger case than the market appreciates," says the firm, which models 70% probability of success and $2B U.S. peak sales for AMT-130.

• Keefe Bruyette upgraded Core Scientific (CORZ) to Outperform from Market Perform with a price target of $28, up from $25. The company delivered a near-term lease win, signing 529 megawatt of direct and indirect AMD (AMD) leases, the firm tells investors in a research note.

Top 5 Downgrades:

• Argus downgraded Las Vegas Sands (LVS) to Hold from Buy. The firm is citing a weak Chinese economy and potential pressure on VIP gaming suggesting ongoing challenges for the company, also stating that in Singapore, the uncertain pace of recovery from Q2 weakness has contributed to a lack of visibility that could cause the earnings multiple to remain compressed.

• Raymond James downgraded Humana (HUM) to Market Perform from Outperform without a price target. Raymond James says there are still a lot of unknown factors and matters out of Humana's control regarding Stars cut points.

• HSBC downgraded Procter & Gamble (PG) to Hold from Buy with a price target of $149, down from $182. The company reported "weak" fiscal Q4 results and its fiscal 2027 guidance points to another transition year with its reinvestments yet to translate into a margin recovery, the firm tells investors in a research note.

• Stifel downgraded SiteOne Landscape (SITE) to Hold from Buy with a price target of $100, down from $153. The firm now believes questions around the share performance will be difficult to counter near-term, "muting bull arguments."

• Piper Sandler downgraded Capricor Therapeutics (CAPR) to Neutral from Overweight with a price target of $2, down from $58. Based on the FDA's negative stance on the HOPE-3 trial, Piper expects the agency will likely issue another complete response letter and not approve deramiocel for the treatment of cardiomyopathy in Duchenne muscular dystrophy by the August 22 action date. Cantor Fitzgerald, Ladenburg, Oppenheimer, Maxim and H.C. Wainwright also downgraded the stock to Neutral-equivalent ratings.

Top 5 Initiations:

• Melius Research initiated coverage of Jersey Mike's Subs (JMKE) with a Buy rating and $30 price target, which offers 30% upside to the $23 offering price. The firm sees a decade of unit-driven growth compounding for the company.

• Freedom Capital initiated coverage of Dave (DAVE) with a Hold rating and $400 price target. Dave has become "one of the best-executing operators in consumer cash-flow based credit," but the firm sees a balanced risk/ reward given a "rich valuation" offering limited support in the event of negative estimate revisions or volatile market conditions.

• Deutsche Bank initiated coverage of Kymera Therapeutics (KYMR) with a Hold rating and $120 price target. The firm sees a full valuation at current share levels.

• Lake Street initiated coverage of Aeon Biopharma (AEON) with a Buy rating and $1 price target. Aeon is developing a biosimilar that has the potential to be approved with all of Botox's indications, creating "a powerful competitor that has an actual chance of taking real market share," the firm tells investors.

• Wedbush analyst Michael Piccolo assumed coverage of Fannie Mae (FNMA) with an Outperform rating and $8 price target following quarterly results. Because Fannie Mae remains in conservatorship, net income sweeps to Treasury rather than flowing to per-share earnings, so there is no traditional EPS beat/miss; the relevant story is capital accretion.